Renal transplantation in HIV-infected patients: 2010 update

Kidney International

Volumn 79, Issue 8, 2011, Pages 825-842

  Trullas, Joan C ^a   Cofan, Federico ^b   Tuset, Montse ^b   Ricart, María J ^b   Brunet, Mercedes ^b   Cervera, Carlos ^b   Manzardo, Christian ^b   López Dieguez, María ^b   Oppenheimer, Federico ^b   Moreno, Asuncion ^b   Campistol, Josep M ^b   Miro, Jose M ^b  

^a UNIVERSITY OF GIRONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

drug interactions; hepatitis C; HIV infection; immunosuppression; kidney failure; kidney transplantation

Indexed keywords

ABACAVIR; ACICLOVIR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN; ANTIRETROVIRUS AGENT; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOSPORIN; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSCARNET; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TACROLIMUS; TENOFOVIR; TENOFOVIR DISOPROXIL; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; BONE MARROW SUPPRESSION; CADAVER DONOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY DISEASE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG POTENTIATION; GRAFT SURVIVAL; HEMODIALYSIS; HEPATITIS C; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVING DONOR; LYMPHOCYTOPENIA; METABOLIC DISORDER; MIXED INFECTION; OPPORTUNISTIC INFECTION; PATIENT SELECTION; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; REVIEW; SURVIVAL RATE; VIRUS LOAD;

EID: 79953245302     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.545     Document Type: Review

References (139)

1. Mocroft A, Brettle R, Kirk O et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: 1663-1671. (Pubitemid 34921112)
2. Miro JM, Aguero F, Laguno M et al. Liver transplantation in HIV/hepatitis co-infection. J HIV Ther 2007; 12: 24-35.
3. Landin L, Rodriguez-Perez JC, Garcia-Bello MA et al. Kidney transplants in HIV-positive recipients under HAART. A comprehensive review and meta-analysis of 12 series. Nephrol Dial Transplant 2010; 25: 3106-3115.
4. Daugas E, Rougier JP, Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int 2005; 67: 393-403. (Pubitemid 40139831)
5. Rö ling J, Schmid H, Fischereder M et al. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006; 42: 1488-1495.
6. Kimmel PL, Barisoni L, Kopp JB. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med 2003; 139: 214-226. (Pubitemid 38124604)
7. Atta MG, Gallant JE, Rahman MH et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006; 21: 2809-2813. (Pubitemid 44542235)
8. Atta MG, Fine DM, Kirk GD et al. Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland. Clin Infect Dis 2007; 45: 1625-1632. (Pubitemid 351411849)
9. Trullas JC, Mocroft A, Cofan F et al. Dialysis and renal transplantation in HIV-infected patients: a European survey. J Acquir Immune Defic Syndr 2010; 55: 582-589.
10. Finelli L, Miller JT, Tokars JI et al. National surveillance of dialysisassociated diseases in the United States, 2002. Semin Dial 2005; 18: 52-61. (Pubitemid 40348277)
11. Rao TKS. Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV), and dialysis. In: Andreucci VE, Fine LG (eds). International Yearbook of Nephrology 1991. Kluwer Academic: Boston, 1990, pp 199-218.
12. Geerlings W, Tufveson G, Brunner FP et al. Combined report on regular dialysis and transplantation in Europe, XXI, 1990. Nephrol Dial Transplant 1991; 6(Suppl 4): 5-29.
13. Barbiano di Belgiojoso G, Trezzi M, Scorza D et al. HIV infection in dialysis centers in Italy: a nationwide multicenter study. J Nephrol 1998; 11: 249-254. (Pubitemid 28511524)
14. Poignet JL, Desassis JF, Chanton N et al. Prevalence of HIV infection in dialysis patients: results of a national multicenter study. Nephrologie 1999; 20: 159-163. (Pubitemid 29297367)
15. Vigneau C, Guiard-Schmid JB, Tourret J et al. The clinical characteristics of HIV-infected patients receiving dialysis in France between 1997 and 2002. Kidney Int 2005; 67: 1509-1514. (Pubitemid 40463128)
16. Barril G, Trullás JC, González-Parra E et al. Prevalence of HIV-1-infection in dialysis units in Spain and potential candidates for renal transplantation: results of a Spanish survey. Enferm Infecc Microbiol Clin 2005; 23: 335-339. (Pubitemid 41020544)
17. Trullàs JC, Barril G, Cofan F et al. Prevalence and clinical characteristics of HIV-1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006. AIDS Res Hum Retroviruses 2008; 24: 1229-1235.
18. Hassan NF, el Ghorab NM, Abdel Rehim MS et al. HIV infection in renal dialysis patients in Egypt. AIDS 1994; 8: 853. (Pubitemid 24163434)
19. Morikawa K, Kuroda M, Tofuku Y et al. Prevalence of ATLV and HIV among hemodialysis patients in Japan. Nephron 1988; 50: 77-78.
20. Falcao HA, Rebelo M. Anti-HIV antibodies in population of 132 patients in hemodialysis (Abstract). Xth International Congress of Nephrology: London, 1987.
21. Ortiz C, Meneses R, Jaffe D et al. Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int 1988; 34: 248-253.
22. Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol 2002; 13: 1889-1893. (Pubitemid 34700614)
23. Trullàs JC, Barril G, Cofan F et al. Outcome and Prognostic Factors in HIV-1-Infected Dialysis Patients in Spain in the HAART Era: A Case-Control GESIDA/SEN Study. 17th CROI (Conference on Retroviruses and Opportunistic Infections, San Francisco, 2010. Abstract 739.
24. Rodriguez RA, Mendelson M, O'Hare AM et al. Determinants of survival among HIV-infected chronic dialysis patients. J Am Soc Nephrol 2003; 14: 1307-1313. (Pubitemid 36514670)
25. Tourret J, Tostivint I, du Montcel ST et al. Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin J Am Soc Nephrol 2006; 1: 1241-1247.
26. Choi AI, Rodriguez RA, Bacchetti P et al. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis 2007; 45: 1633-1639. (Pubitemid 351411850)
27. Solid Organ Transplantation in HIV: Multi-Site Study [Last accessed 19 August 2010]. Available at: www.hivtransplant.com.
28. Anonymous. Solid organ transplantation in the HIV-infected patient. Am J Transplant 2004; 4(Suppl 10): 83-88.
29. Miro JM, Torre-Cisneros J, Moreno A et al. GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005). Enferm Infecc Microbiol Clin 2005; 23: 353-362. (Pubitemid 41020547)
30. Bhagani S, Sweny P, Brook G. Guidelines for kidney transplantation in patients with HIV disease. HIV Med 2006; 7: 133-139.
31. Grossi P, Tumietto F, Costigliola P et al. Liver transplantation in HIV-infected individuals: results of the Italian national program. Transplantation 2006; 82(Suppl 2): 446.
32. Epstein AM, Ayanian JZ, Keogh JH et al. Racial disparities in access to renal transplantation-clinically appropriate or due to underuse or overuse? N Engl J Med 2000; 343: 1537-1544.
33. Sawinski D, Wyatt CM, Casagrande L et al. Factors associated with failure to list HIV-positive kidney transplant candidates. Am J Transplant 2009; 9: 1-5.
34. Schwarz A, Offermann G, Keller F et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation-data on four cases and review of the literature. Transplantation 1993; 55: 95-103. (Pubitemid 23033953)
35. Trullás JC, Miró JM, Barril G et al. Renal transplantation in patients with HIV infection. Enferm Infecc Microbiol Clin 2005; 23: 363-374. (Pubitemid 41020548)
36. Feduska NJ, Perkins HA, Melzer J et al. Observations relating to the incidence of the acquired immune deficiency syndrome and other possibly associated conditions in a large population of renal transplant recipients. Transplant Proc 1987; 19: 2161-2166.
37. Kumar P, Pearson JE, Martín DH et al. Transmission of human immunodeficiency virus by transplantation of a renal allograft, with development of the acquired immunodeficiency syndrome. Ann Intern Med 1987; 106: 244-245. (Pubitemid 17009887)
38. Imbasciati E, De Cristofaro V, Sama F et al. Acquired immunodeficiency syndrome transmitted by transplanted kidney: clinical course during maintenance haemodialysis. Nephrol Dial Transplant 1988; 3: 681-683. (Pubitemid 19001002)
39. Milgrom M, Esquenazi V, Fuller L et al. Acquired immunodeficiency syndrome in a transplant patient. Transplant Proc 1985; 17(Suppl 2): 75.
40. Lang P, Buisson C, Foucher A et al. Unusual immune deficiency syndrome associated with LAV/HTLV-III in a kidney transplant recipient. Transplant Proc 1986; 18: 1400.
41. Poli F, Scalamonga M, Pizzi C et al. HIV infection in cadaveric renal allograft recipients in the North Italy Transplant Program. Transplantation 1989; 47: 724-725. (Pubitemid 19110937)
42. Erice A, Rhame FS, Heussner RC et al. HIV infection in patients with solid-organ transplants: report of five cases and review. Rev Infect Dis 1991; 13: 537-547.
43. Prompt CA, Reis MM, Grillo FM et al. Transmission of AIDS virus at renal transplantation. Lancet 1985; 2: 672. (Pubitemid 15239370)
44. L'age-Stehr J, Schwarz A, Offermann G et al. HTLV-III infection in kidney transplant recipients. Lancet 1985; 2: 1361-1362. (Pubitemid 16175443)
45. Schwarz A, Hoffmann F, L'age-Stehr J et al. Human immunodeficiency virus transmission by organ donation. Outcome in cornea and kidney recipients. Transplantation 1987; 44: 21-24.
46. Margreiter R, Fuchs D, Hausen A et al. HIV infection in renal allograft recipients. Lancet 1986; 2: 398. (Pubitemid 16036525)
47. Briner V, Zimmerli W, Cathomas G et al. HIV infection caused by kidney transplant: case report and review of 18 published cases. Schweiz Med Wochenschr 1989; 119: 1046-1052. (Pubitemid 19193971)
48. Ahuja TS, Zingman B, Glicklich D. Long-term survival in an HIV-infected transplant recipient. Am J Nephrol 1997; 17: 480-482. (Pubitemid 27425108)
49. Simonds RJ, Holmberg SD, Hurwitz RL et al. Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. N Engl J Med 1992; 326: 726-732.
50. Bowen PA, Lobel SA, Caruana RJ et al. Transmission of human immunodeficiency virus (HIV) by transplantation: clinical aspects and time course analysis of viral antigenemia and antibody production. Ann Intern Med 1988; 108: 46-48. (Pubitemid 18081169)
51. Ward JW, Schable C, Dickinson GM et al. Acute human immunodeficiency virus infection. Antigen detection and seroconversion in immunosuppressed patients. Transplantation 1989; 47: 722-724. (Pubitemid 19110936)
52. Kerman RH, Flechner SM, Van Buren CT et al. Investigation of human T-lymphotropic virus III serology in a renal transplant population. Transplant Proc 1987; 19: 2172-2175.
53. Carbone LG, Cohen DJ, Hardy MA et al. Determination of acquired immunodeficiency syndrome (AIDS) after renal transplantation. Am J Kidney Dis 1988; 11: 387-392.
54. Tzakis AG, Cooper MH, Dummer JS et al. Transplantation in HIV+ patients. Transplantation 1990; 49: 354-358.
55. Swanson SJ, Kirk AD, Ko CW et al. Impact of HIV seropositivity on graft and patient survival after cadaveric renal transplantation in the United States in the pre highly active antiretroviral therapy (HAART) era: an historical cohort analysis of the United States Renal Data System. Transpl Infect Dis 2002; 4: 144-147. (Pubitemid 35364778)
56. Abbott KC, Swanson SJ, Agodoa LY et al. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004; 15: 1633-1639. (Pubitemid 38679689)
57. Qiu J, Terasaki PI, Waki K et al. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation 2006; 81: 1658-1661. (Pubitemid 43948298)
58. Kuo PC, Stock PG. Transplantation in the HIV+ patient. Am J Transplant 2001; 1: 13-17. (Pubitemid 33681675)
59. Stock P, Roland M, Carlson L et al. Solid organ transplantation in HIV-positive patients. Transplant Proc 2001; 33: 3646-3648. (Pubitemid 34042715)
60. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003; 75: 425-429. (Pubitemid 36241132)
61. Toso C, Berney T, Oberholzer J et al. Kidney-pancreas transplantation in a long-term non-progressor HIV-infected recipient. Am J Transplant 2003; 3: 631-633. (Pubitemid 36612848)
62. Kumar AM, Damask A, Roland M et al. Kidney transplantation in HIV positive end stage renal disease patients-a prospective study. Am J Transplant 2002; 2: 174.
63. Stock PG, Roland ME, Carlson L et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003; 76: 370-375. (Pubitemid 36928001)
64. Mazuecos A, Pascual J, Gómez E et al. Renal transplantation in HIV-infected patients in Spain. Nefrologia 2006; 26: 113-120. (Pubitemid 44898068)
65. Kumar MS, Sierka DR, Damask AM et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005; 67: 1622-1629. (Pubitemid 40463144)
66. Roland ME, Barin B, Carlson L et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8: 355-365.
67. Gruber SA, Doshi MD, Cincotta E et al. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation 2008; 86: 269-274.
68. Mü ller NJ, Furrer H, Kaiser L et al. HIV and solid organ transplantation: the Swiss experience. Swiss Med Wkly 2006; 136: 194-196.
69. Ballarin R, Di Benedetto F, Masetti M et al. Combined liver-kidney transplantation in an HIV-HCV-coinfected patient with haemophilia. AIDS 2008; 22: 2047-2049.
70. Trullas JC, Cofan F, Cocchi S et al. Effect of thymoglobulin induction on HIV-infected renal transplant recipients: differences between HIV-positive and HIV-negative patients. AIDS Res Hum Retroviruses 2007; 23: 1161-1165. (Pubitemid 350014766)
71. Mazuecos A, Fernández A, Andrés A et al. Infección VIH y trasplante renal: un estudio de casos y controles en España. 1er Congreso de la Sociedad Españ ola de Trasplante: Sevilla; 2-5 Junio 2010. Abstract no. 72
72. Billault C, Duvivier C, Valantin MA et al. Kidney transplantation in HIV-positive patients: report of our first 7 cases. Transplant Proc 2009; 41: 3301-3304.
73. Touzot M, Pillebout E, Matignon M et al. Renal transplantation in HIV-infected patients: the Paris experience. Am J Transplant 2010; 10: 2263-2269.
74. Stock PG, Barin B, Murphy B et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363: 2004-2201.
75. Tricot L, Teicher E, Peytavin G et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9: 1-7.
76. Schnickel GT, Bastani S, Hsieh GR et al. Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection. J Immunol 2008; 180: 4714-4721.
77. Fischereder M, Luckow B, Hocher B et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001; 357: 1758-1761. (Pubitemid 32524207)
78. Gupta SK, Eustace JA, Winston JA et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 1559-1585. (Pubitemid 40720806)
79. Panel de expertos de Gesida; Plan Nacional sobre el Sida. AIDS Study Group/Spanish AIDS Plan consensus document on antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010). Enferm Infecc Microbiol Clin 2010; 28: 362.e1-362.e91.
80. Antiretroviral agents product information. European Medicines Agency (EMEA). EPARs for authorised medicinal products for human use Available at: http://www.emea.europa.eu/htms/human/epar/a.htm (accessed 10 March 2010).
81. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-333.
82. Gupta SK, Rosenkranzb SL, Cramerb YS et al. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS 2008; 22: 1919-1927.
83. Guardiola JM, Mangues MA, Domingo P et al. Indinavir pharmacokinetics in haemodialysis-dependent end-stage renal failure. AIDS 1998; 12: 1395. (Pubitemid 28330736)
84. Jayasekara D, Aweeka FT, Rodriguez R et al. Antiviral therapy for HIV patients with renal insufficiency. J Acquir Immune Defic Syndr 1999; 21: 384-395. (Pubitemid 29384000)
85. Paci-Bonaventure S, Hafi A, Vincent I et al. Lack of removal of nelfinavir during a haemodialysis session in an HIV-1 infected patient with hepatic and renal insufficiency. Nephrol Dial Transplant 2001; 16: 642-643. (Pubitemid 32229310)
86. Kearney BP, Yale K, Shah J et al. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin Pharmacokinet 2006; 45: 1115-1124. (Pubitemid 44631390)
87. Chen L, Sabo JP, Philip E et al. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir. Antimicrob Agents Chemother 2007; 51: 2436-2444. (Pubitemid 47047322)
88. Gill MJ, Ostrop NJ, Fiske WD et al. Efavirenz dosing in patients receiving continuous ambulatory peritoneal dialysis. AIDS 2000; 14: 1062-1064. (Pubitemid 30336070)
89. Izzedine H, Launay-Vacher V, Jullien V et al. Pharmacokinetics of tenofovir in haemodialysis. Nephrol Dial Transplant 2003; 18: 1931-1933. (Pubitemid 37098571)
90. King JR, Acosta EP. Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clin Pharmacokinet 2006; 45: 665-682. (Pubitemid 43990569)
91. Tebas P, Bellos N, Lucasti C et al. Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function. J Acquir Immune Defic Syndr 2008; 47: 342-345. (Pubitemid 351619421)
92. Agarwala S, Eley T, Child M et al. Pharmacokinetics of atazanavir in severely renally impaired subjects including those on hemodialysis. 8th International Workshop on Clinical Pharmacology of HIV Therapy. Budapest, Hungary, 16-18 April, 2007. Abstract 2.
93. Petry S, Hanley WD, Silk G et al. Effect of severe renal insufficiency on raltegravir pharmacokinetics. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2007. Abstract A-1424.
94. McIntyre J, Hughes M, Mellors J et al. Efficacy of ART with NVP-TDF/FTC vs LPV/r-TDF/FTC among antiretroviral-naive women in Africa: OCTANE Trial 2/ACTG A5208. In: 17th Conference on Retroviruses and Opportunistic Infections. CROI: San Francisco, CA, 2010. Abstract 153LB.
95. Pulido F, Arribas JR, Delgado R et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22: F1-F9.
96. Arribas JR, Horban A, Gerstoft J et al. The MONET trial: darunavir/ ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010; 24: 223-230.
97. Venter WD, Naicker S, Dhai A et al. Uniquely South African: time to consider offering HIV-positive donor kidneys to HIV-infected renal failure patients? S Afr Med J 2008; 98: 182-183. (Pubitemid 351516340)
98. Muller E, Kahn D, Mendelson M. Renal transplantation between HIV-positive donors and recipients. N Engl J Med 2010; 362: 2336-2337.
99. Cofan F, Trullas JC, Cervera C et al. Are HIV-infected donors suitable for renal transplantation? Transplantation 2011; 91: In press. DOI: 10.1097/TP.0b013e318206fa5d.
100. Ciuffreda D, Pantaleo G, Pascual M. Effects of immunosuppressive drugs on HIV infection: implications for solid-organ transplantation. Transpl Int 2007; 20: 649-658. (Pubitemid 47024913)
101. Streblow DN, Kitabwalla M, Malkovsky M et al. Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A. Virology 1998; 245: 197-202. (Pubitemid 28394182)
102. Chapuis AG, Paolo Rizzardi G, D'Agostino C et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000; 6: 762-768. (Pubitemid 30469424)
103. Hossain MM, Coull JJ, Drusano GL et al. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res 2002; 55: 41-52. (Pubitemid 34655641)
104. Sankatsing SU, Hoggard PG, Huitema AD et al. Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clin Pharmacokinet 2004; 43: 823-832. (Pubitemid 39382222)
105. Gilliam BL, Heredia A, Devico A et al. Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment. AIDS 2007; 21: 2108-2110. (Pubitemid 47462163)
106. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323. (Pubitemid 40411498)
107. Bosch RJ, Pollard RB, Landay A et al. Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328). AIDS Res Ther 2010; 7: 30.
108. Carter JT, Melcher ML, Carlson LL et al. Thymoglobulin-associated CD4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant 2006; 6: 753-760. (Pubitemid 43345013)
109. Moscoso-Solorzano GT, Baltar JM, Seco M et al. Single dose of rituximab plus plasmapheresis in an HIV patient with acute humoral kidney transplant rejection: a case report. Transplant Proc 2007; 39: 3460-3462. (Pubitemid 350251517)
110. Brinkman K, Huysmans F, Burger DM. Pharmacokinetic interaction between saquinavir and cyclosporine. Ann Intern Med 1998; 129: 914-915.
111. Barrail-Tran A, Furlan V, Blouin P et al. Effect of coadministered boosted protease inhibitors regimen on tacrolimus blood concentration in 3 kidney transplanted HIV-infected patients. 8th International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hungary, 2007. Abstract 58.
112. Jain AK, Venkataramanan R, Shapiro R et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002; 8: 841-845. (Pubitemid 35012297)
113. Tseng A, Nguyen ME, Cardella C et al. Probable interaction between efavirenz and cylcosporine. AIDS 2002; 16: 505-506.
114. Frassetto LA, Browne M, Cheng A et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816-2820. (Pubitemid 350045781)
115. Teicher E, Vittecoq D, Taubert AM et al. Liver transplantation in HIV-coinfected patients treated with enfuvirtide. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, USA, 2006. Abstract 874.
116. Moreno A, Bárcena R, Quereda C et al. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation. AIDS 2008; 22: 547-548. (Pubitemid 351317304)
117. Guaraldi G, Cocchi S, Codeluppi M et al. Pharmacokinetic interaction between amprenavir/ritonavir and fosamprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplant Proc 2006; 38: 1138-1140. (Pubitemid 43815874)
118. Margolis DM, Kewn S, Coull JJ et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002; 31: 45-49.
119. Regazzi M, Villani P, Lapoce R et al. Pharmacokinetic evaluation of antiretroviral and immunosuppressive therapy in acute HIV infection following solid-organ transplantation. 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, LA, 2008. Abstract P53.
120. Neff GW, Bonham A, Tzakis AG et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239-247. (Pubitemid 36322325)
121. Schonder KS, Schullo MA, Okusanya O. Tacrolimus and lopinavir/ ritonavir interaction in liver transplantation. Ann Pharmacother 2003; 37: 1793-1796. (Pubitemid 37466573)
122. Sheikh AM, Wolf DC, Lebovics E et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 1999; 68: 307-309. (Pubitemid 29360297)
123. Vogel M, Voigt E, Michaelis HC et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004; 10: 939-944. (Pubitemid 38979268)
124. Tuset M, Miro JM, Codina C et al. eds. Antiretroviral agents drug-drug interactions website (Spanish). Available at: http:// www.interaccioneshiv.com/ (accessed 10 March 2010).
125. Back D, Gibbons S. The University of Liverpool HIV drug interactions website: http://www.hiv-druginteractions.org (accessed 10 March 2010).
126. Certican (everolimus) product information. Novartis Pharma Stein AG: Switzerland. Available at: http://www.health.gov.il/units/pharmacy/ trufot/alonim/2256.pdf (accessed 10 March 2010).
127. Prograf (tacrolimus) prescribing information. Astellas Pharma US. Available at: http://www.astellas.us/docs/prograf.pdf [accessed 4 January 2011].
128. Rapamune (sirolimus) product information. European Medicines Agency (EMEA). EPARs for authorised medicinal products for human use. Available at: http://www.emea.europa.eu/htms/human/epar/a.htm (accessed 10 March 2010).
129. Sandimmune (cyclosporine) product information. Novartis Pharmaceuticals Corporation: East Hanover, New Jersey, 2007 Available at: http://www.pharma.us. novartis.com/product/pi/pdf/ sandimmune.pdf (accessed 10 March 2010).
130. Abbott KC, Lentine KL, Bucci JR et al. The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004; 4: 2032-2037. (Pubitemid 39611631)
131. Mahmoud IM, Elhabashi AF, Elsawy E et al. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am J Kidney Dis 2004; 43: 131-139. (Pubitemid 38049444)
132. Teta D, Luscher BL, Gonvers JJ et al. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 2005; 20: 991-993. (Pubitemid 40704040)
133. Fontaine H, Vallet-Pichard A, Equi-Andrade C et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78: 853-857. (Pubitemid 39298528)
134. Kamar N, Izopet J, Alric L et al. Lack of evidence for ribavirin monotherapy efficacy on liver fibrosis in hepatitis C virus positive renal transplant patients. Transplantation 2005; 79: 1770-1771. (Pubitemid 40885285)
135. Vanrenterghem YF, Claes K, Montagnino G et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008; 85: 209-216. (Pubitemid 351222383)
136. Fine DM, Perazella MA, Lucas GM et al. Renal disease in patients with HIV infection: epidemiology, pathogenesis and management. Drugs 2008; 68: 963-980. (Pubitemid 351652924)
137. Roland ME, Lo B, Braff J et al. Key clinical, ethical, and policy issues in the evaluation of the safety and effectiveness of solid organ transplantation in HIV-infected patients. Arch Intern Med 2003; 163: 1773-1778. (Pubitemid 36960921)
138. Miro JM, Ricart MJ, Trullas JC et al. Pancreas-kidney transplantation in an HIV-infected patient treated with raltegravir: case report and literature review. Transplant Proc 2010; 42: 3887-3891.
139. Genzini T, Noujaim HM, Mota LT et al. Simultaneous pancreas-kidney transplantation in a human immunodeficiency virus-positive recipient: a case report. Transplant Proc 2010; 42: 591-593.